RUNX1 and acute lymphoblastic leukemia: Although characterized by nearly identical global gene expression profiles, ETV6-RUNX1-like and ETV6-RUNX1 ALL showed notable differences in drug sensitivity: ETV6-RUNX1-like ALL was more resistant to L-asparaginase (LC50 0.55 compared to 0 in ETV6-RUNX1, P = 0.013; Fig. 2b) but had increased sensitivity to trametinib (LC50 0.20 versus 1.0, P = 0.002; Extended Data Fig. 3b).